Q2 Earnings Forecast for Alumis Issued By Leerink Partnrs

Alumis Inc. (NASDAQ:ALMS) – Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Alumis in a research report issued to clients and investors on Sunday, March 23rd. Leerink Partnrs analyst T. Smith expects that the company will earn ($1.48) per share for the quarter. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share. Leerink Partnrs also issued estimates for Alumis’ Q3 2025 earnings at ($1.38) EPS, Q4 2025 earnings at ($1.28) EPS, FY2025 earnings at ($5.46) EPS, FY2026 earnings at ($5.19) EPS, FY2027 earnings at ($6.13) EPS, FY2028 earnings at ($3.99) EPS and FY2029 earnings at ($2.04) EPS.

A number of other equities analysts also recently commented on ALMS. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Alumis in a research note on Wednesday. Oppenheimer initiated coverage on Alumis in a research report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 target price for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research report on Thursday, March 20th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $26.00.

Alumis Price Performance

ALMS opened at $4.92 on Wednesday. The company has a 50-day moving average of $5.49 and a 200-day moving average of $8.40. Alumis has a 1-year low of $3.18 and a 1-year high of $13.53.

Institutional Trading of Alumis

Several hedge funds have recently made changes to their positions in the stock. Tang Capital Management LLC increased its position in Alumis by 40.6% in the fourth quarter. Tang Capital Management LLC now owns 600,000 shares of the company’s stock worth $4,716,000 after buying an additional 173,406 shares during the period. Foresite Capital Management V LLC grew its position in shares of Alumis by 3.5% during the fourth quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock worth $45,426,000 after acquiring an additional 194,459 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Alumis by 1,257.0% in the 4th quarter. BNP Paribas Financial Markets now owns 34,835 shares of the company’s stock worth $274,000 after acquiring an additional 32,268 shares during the period. Ally Bridge Group NY LLC lifted its position in Alumis by 6.4% in the 4th quarter. Ally Bridge Group NY LLC now owns 445,259 shares of the company’s stock valued at $3,500,000 after purchasing an additional 26,843 shares during the last quarter. Finally, Foresite Capital Management VI LLC acquired a new position in Alumis during the 4th quarter valued at about $33,033,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.